Premium
High‐dose chemotherapy and autologous peripheral blood stem cell transplantation in high‐risk multiple myeloma
Author(s) -
Murakami Hirokazu,
Fujii Hiroshi,
Inaba Tohru,
Shimazaki Chihiro,
Okamoto Sinichirou,
Miwa Akiyosi,
Sawamura Morio,
Abe Masahiro,
Chou Takaaki,
Asaoku Hideki,
Kitahara Yoshikazu,
Hayashi Kunihiko,
Kosaka Masaaki,
Togawa Atsushi,
Takatsuki Kiyoshi
Publication year - 2004
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.2004.00282.x
Subject(s) - medicine , multiple myeloma , beta 2 microglobulin , risk stratification , chemotherapy , autologous stem cell transplantation , transplantation , oncology , gastroenterology , peripheral , multivariate analysis , peripheral blood
We compared the effect of high‐dose therapy together with autologous peripheral blood stem cell transplantation (autoPBSCT) in 60 patients with multiple myeloma (MM) with 90 patients who underwent conventional chemotherapy. We scored the prognostic factors according to our reported classification system that includes measurements of serum albumin, serum beta‐2‐microglobulin, and morphology of myeloma cells selected by multivariate analysis. We separated the patients into three risk groups at stratification level I (low, intermediate and high) and into two risk groups at stratification level II (low and high). AutoPBSCT tended to be as effective for high, as for low‐risk patients in level I, and was obviously as helpful for high, as for low‐risk patients in stratification II. In conclusion, high‐risk patients with MM should be treated with high‐dose therapy accompanied with autoPBSCT like low‐risk patients.